Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherHot Topics (Invitation Only)

Landscape analysis of phase 2/3 clinical trials of targeted radionuclide therapy

Erik Mittra, Amanda Abbott and Lisa Bodei
Journal of Nuclear Medicine February 2021, jnumed.120.258103; DOI: https://doi.org/10.2967/jnumed.120.258103
Erik Mittra
1 OHSU, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Abbott
2 Society of Nuclear Medicine & Molecular Imaging;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Bodei
3 Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Landscape analysis of phase 2/3 clinical trials of targeted radionuclide therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Landscape analysis of phase 2/3 clinical trials of targeted radionuclide therapy
Erik Mittra, Amanda Abbott, Lisa Bodei
Journal of Nuclear Medicine Feb 2021, jnumed.120.258103; DOI: 10.2967/jnumed.120.258103

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Landscape analysis of phase 2/3 clinical trials of targeted radionuclide therapy
Erik Mittra, Amanda Abbott, Lisa Bodei
Journal of Nuclear Medicine Feb 2021, jnumed.120.258103; DOI: 10.2967/jnumed.120.258103
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Hot Topics (Invitation Only)

  • Hot Topic, Why will PET be the future of nuclear cardiology?
  • Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics
Show more Hot Topics (Invitation Only)

Clinical (Radionuclide Therapy)

  • Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients
  • First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients
Show more Clinical (Radionuclide Therapy)

Similar Articles

Keywords

  • Oncology: General
  • Radionuclide Therapy
  • Research Methods
  • radioisotope therapy
  • radioligand therapy
  • radiopharmaceutical therapy
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire